Personal information

No personal information available

Activities

Collapse all

Works (5)

Tofacitinib and faecal microbiota transplantation in treating checkpoint inhibitor-induced enterocolitis: case report

BMJ Open Gastroenterology
2022-12 | Journal article
DOI: 10.1136/bmjgast-2022-000989
Contributors: Rikke Boedker Holmstroem; Emilie Kristine Dahl; Morten Helms; Henrik Vedel Nielsen; Janne Bayer Andersen; Jacob Tveiten Bjerrum; Inge Marie Svane; Eva Ellebaek; Jakob Benedict Seidelin
Source: check_circle
Crossref

COLAR: open-label clinical study of IL-6 blockade with tocilizumab for the treatment of immune checkpoint inhibitor-induced colitis and arthritis

Journal for ImmunoTherapy of Cancer
2022-09 | Journal article
DOI: 10.1136/jitc-2022-005111
Contributors: Rikke Boedker Holmstroem; Ole Haagen Nielsen; Søren Jacobsen; Lene Buhl Riis; Susann Theile; Jacob Tveiten Bjerrum; Peter Vilmann; Julia Sidenius Johansen; Mogens Karsbøl Boisen; Rikke Helene Løvendahl Eefsen et al.
Source: check_circle
Crossref

Author Correction: A phase 1/2 trial of an immune-modulatory vaccine against IDO/PD-L1 in combination with nivolumab in metastatic melanoma

Nature Medicine
2022-04 | Journal article
DOI: 10.1038/s41591-022-01771-w
Contributors: Julie Westerlin Kjeldsen; Cathrine Lund Lorentzen; Evelina Martinenaite; Eva Ellebaek; Marco Donia; Rikke Boedker Holmstroem; Tobias Wirenfeldt Klausen; Cecilie Oelvang Madsen; Shamaila Munir Ahmed; Stine Emilie Weis-Banke et al.
Source: check_circle
Crossref

A phase 1/2 trial of an immune-modulatory vaccine against IDO/PD-L1 in combination with nivolumab in metastatic melanoma

Nature Medicine
2021-12 | Journal article
DOI: 10.1038/s41591-021-01544-x
Contributors: Julie Westerlin Kjeldsen; Cathrine Lund Lorentzen; Evelina Martinenaite; Eva Ellebaek; Marco Donia; Rikke Boedker Holmstroem; Tobias Wirenfeldt Klausen; Cecilie Oelvang Madsen; Shamaila Munir Ahmed; Stine Emilie Weis-Banke et al.
Source: check_circle
Crossref

Clinical efficacy and immunity of a novel immune-modulatory peptide vaccine against IDO/PD-L1 (IO102/IO103) in combination with nivolumab in patients with metastatic melanoma

2021-03-01 | Preprint
DOI: 10.21203/rs.3.rs-257411/v1
Contributors: Julie Kjeldsen; Cathrine Lorentzen; Evelina Martinenaite; Eva Ellebaek; Marco Donia; Rikke Holmstroem; Tobias Klausen; Helle Hendel; Eva Ehrnrooth; Mai-Britt Zocca et al.
Source: check_circle
Crossref
How many people are using ORCID?